Library Item - Page 48 of 792 Posts on Medivizor

Effects of combined treatment with venetoclax, daratumumab and dexamethasone with or without bortezomib in patients with relapsed or refractory multiple myeloma.

$Effects of combined treatment with venetoclax, daratumumab and dexamethasone with or without bortezomib in patients with relapsed or refractory multiple myeloma.$

Posted by Medivizor on Sep 19, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of a venetoclax (Venclexta), daratumumab (Darzalex), and dexamethasone (Decadron combination with or without bortezomib (Velcade) in patients with relapsed or refractory (RR) multiple myeloma (MM). The authors concluded that these treatment combinations produced high...

Does reduced intensity conditioning hematopoietic stem cell transplantation improve the outcomes of patients with chronic lymphocytic leukemia and Richter’s transformation?

Posted by Medivizor on Sep 19, 2021 in Leukemia | 0 comments

In a nutshell The study aimed to investigate whether reduced-intensity conditioning (RIC) hemopoietic stem cell transplantation (HSCT) improves the outcomes of patients with chronic lymphocytic leukemia (CLL) with and without Richter's transformation (RT). This study concluded that this treatment may be suitable in early...

Venetoclax with intensive chemotherapy in younger patients with newly diagnosed acute myeloid leukemia

Posted by Medivizor on Sep 19, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of venetoclax (Venclexta) combined with intensive chemotherapy in patients aged 65 or younger with acute myeloid leukemia (AML). This study concluded that venetoclax added to intensive chemotherapy was safe and effective in these...

Does long-term ticagrelor treatment improve outcomes in patients with previous percutaneous coronary intervention?

Posted by Medivizor on Sep 19, 2021 in Coronary artery disease | 0 comments

In a nutshell This study looked at long-term treatment with ticagrelor (Brilique) after percutaneous coronary intervention (PCI) in patients with coronary artery disease (CAD). It found that compared to patients treated with placebo, those treated with ticagrelor were less likely to have a major cardiovascular event (MACE). Some...

Does long-term physiotherapy benefit patients with Parkinson’s disease?

Posted by Medivizor on Sep 17, 2021 in Parkinson's Disease | 0 comments

In a nutshell This study looked at the effects of long-term physiotherapy (6 months or more) on patients with Parkinson's disease. It found that patients doing long-term physiotherapy had fewer symptoms during the "off" medication phase, and needed lower doses of levodopa (Sinemet) to manage their symptoms compared to patients not...

Which combination of treatments is better for HER2 positive advanced breast cancer?

Posted by Medivizor on Sep 17, 2021 in Breast cancer | 0 comments

In a nutshell This study compared two treatment regimes for HER2 positive breast cancer; pyrotinib (Irene) plus vinorelbine (Navelbine), or lapatinib (Tykerb) plus capecitabine (Xeloda). It found that pyrotinib plus vinorelbine (PV) improved survival without cancer progressing compared to lapatinib plus capecitabine (LC). Some background...

Is colchicine beneficial in the management of coronary artery disease?

Posted by Medivizor on Sep 17, 2021 in Coronary artery disease | 0 comments

In a nutshell This study looked at the use of colchicine (Colcrys) in patients with coronary artery disease (CAD). It found that colchicine reduced the risk of heart attack and stroke in these patients. Some background CAD is a condition affecting the blood vessels in the heart. It leads to narrow or blocked blood vessels. It can...

Which is the best approach for treating lateral lymph node metastasis in locally advanced rectal cancer?

Posted by Medivizor on Sep 17, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the best approach for treating lateral lymph node (LLNs) metastasis in patients with locally advanced rectal cancer (LARC). The data showed that a radiation dose boost is an effective way of increasing the response rate and decreasing recurrence rates in these patients. Some background Rectal cancer (RC) is one...

Does early use of high-dose glucocorticoids affect survival in patients with advanced melanoma treated with anti-PD-1 therapy?

Posted by Medivizor on Sep 17, 2021 in Melanoma | 0 comments

In a nutshell This study evaluated the use of high-dose glucocorticoids (GCs) and their impact on the survival outcomes during anti-PD-1 therapy for the treatment of patients with advanced melanoma. The data showed that early high-dose GC use was associated with poorer outcomes after the onset of immune-related side effects. Some background...

Real-world clinical outcomes for patients with chronic myeloid leukemia who needed to switch from second generation TKI therapy.

Posted by Medivizor on Sep 16, 2021 in Leukemia | 0 comments

In a nutshell This study described real-world outcomes for patients with chronic myeloid leukemia (CML) that started a second-generation tyrosine kinase inhibitor (TKI) therapy and needed to switch to an alternative TKI. The authors concluded that intolerance was the major reason to switch to an alternative TKI and that outcomes were very good...

How effective is a netupitant and palonosetron combination in preventing nausea and vomiting in patients with multiple myeloma?

Posted by Medivizor on Sep 16, 2021 in Multiple Myeloma | 0 comments

In a nutshell This study assessed the effectiveness of netupitant/palonosetron (NEPA; Akynzeo) in preventing nausea and vomiting in patients with multiple myeloma (MM) while receiving high-dose melphalan (HDM; Alkeran) and autologous stem cell transplantation (ASCT). The data showed that NEPA, without dexamethasone (DXM; Decadron), was...

Do tyrosine kinase inhibitors benefit patients with mutant inoperable NSCLC?

Posted by Medivizor on Sep 16, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated whether patients with unresectable non-small-cell lung cancer (NSCLC) having genetic mutations could benefit from first-line treatment with tyrosine kinase inhibitor (TKI) therapy. The data showed that TKIs could be a good option for these patients. Some background NSCLC is the most common form of lung cancer....

Library Item Posts on Medivizor

Effects of combined treatment with venetoclax, daratumumab and dexamethasone with or without bortezomib in patients with relapsed or refractory multiple myeloma.

Does reduced intensity conditioning hematopoietic stem cell transplantation improve the outcomes of patients with chronic lymphocytic leukemia and Richter’s transformation?

Venetoclax with intensive chemotherapy in younger patients with newly diagnosed acute myeloid leukemia

Does long-term ticagrelor treatment improve outcomes in patients with previous percutaneous coronary intervention?

Does long-term physiotherapy benefit patients with Parkinson’s disease?

Which combination of treatments is better for HER2 positive advanced breast cancer?

Is colchicine beneficial in the management of coronary artery disease?

Which is the best approach for treating lateral lymph node metastasis in locally advanced rectal cancer?

Does early use of high-dose glucocorticoids affect survival in patients with advanced melanoma treated with anti-PD-1 therapy?

Real-world clinical outcomes for patients with chronic myeloid leukemia who needed to switch from second generation TKI therapy.

How effective is a netupitant and palonosetron combination in preventing nausea and vomiting in patients with multiple myeloma?

Do tyrosine kinase inhibitors benefit patients with mutant inoperable NSCLC?

Categories

Recent Posts

Archives

Library Item Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email